Gabather AB (publ) (FRA:5J2)

Market Cap	2.20M +115.8%
Revenue (ttm)	n/a
Net Income	-490.57K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0002
Previous Close	0.0002
Day's Range	0.0002 - 0.0002
52-Week Range	0.0002 - 0.0150
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About Gabather AB

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer’s disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer’s disease, schizophrenia, and major depressive disorders. The company was incorporated in 2014 and is based in Södertälje, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5J2

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error